2023
PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens
Damo M, Hornick N, Venkat A, William I, Clulo K, Venkatesan S, He J, Fagerberg E, Loza J, Kwok D, Tal A, Buck J, Cui C, Singh J, Damsky W, Leventhal J, Krishnaswamy S, Joshi N. PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens. Nature 2023, 619: 151-159. PMID: 37344588, PMCID: PMC10989189, DOI: 10.1038/s41586-023-06217-y.Peer-Reviewed Original ResearchConceptsEffector CD8 T cellsCD8 T cellsAntigen-specific effector CD8 T cellsAntigen-specific CD8 T cellsAntigen-expressing cellsT cell tolerancePD-1T cellsAdverse eventsCell toleranceCD8 T cell toleranceImmune-related adverse eventsPeripheral T cell repertoirePeripheral T cell toleranceNon-lesional skinT cell repertoireT-cell antigensPeripheral toleranceCheckpoint receptorsSkin biopsiesLocal infiltrationLocal pathologyCell repertoireMouse modelSkin tolerance
2022
Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management
Pach J, Leventhal J. Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management. Critical Reviews In Immunology 2022, 42: 1-20. PMID: 37022356, DOI: 10.1615/critrevimmunol.2023046895.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsCheckpoint inhibitorsT cellsAdverse eventsCutaneous immune-related adverse eventsImmune checkpoint inhibitor therapyInhibition of T cellsOveractivation of T cellsCheckpoint inhibitor therapyImmune checkpoint inhibitorsCutaneous adverse eventsStevens-Johnson syndromeCutaneous autoimmune diseasesToxic epidermal necrolysisPre-existing diseaseLife-threatening eruptionsInhibitor therapyTreatment interruptionImmune dysregulationImmune surveillanceMaculopapular eruptionEpidermal necrolysisAutoimmune diseasesBullous dermatosisAntitumor activity